Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study
✍ Scribed by Clive Holmes; Vivienne Hopkins; Christine Hensford; Vanessa MacLaughlin; David Wilkinson; Henry Rosenvinge
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 49 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-6230
- DOI
- 10.1002/gps.593
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
To determine whether aromatherapy with lavender oil is effective in the treatment of agitated behaviour in patients with severe dementia.
Design
A placebo controlled trial with blinded observer rater.
Setting
A long‐stay psychogeriatric ward.
Patients
Fifteen patients meeting ICD‐10 diagnostic criteria for severe dementia and suffering from agitated behaviour defined as a minimum score of three points on the Pittsburgh Agitation Scale (PAS).
Intervention
A 2% lavender oil aromatherapy stream was administered on the ward for a two hour period alternated with placebo (water) every other day for a total of ten treatment sessions.
Assessments
For each subject 10 total PAS scores were obtained. Five during treatment and five during placebo periods.
Results
Nine patients (60%) showed an improvement, five (33%) showed no change and one patient (7%) showed a worsening of agitated behaviour during aromatherapy compared with placebo. A comparison of the group median PAS scores during aromatherapy showed a significant improvement in agitated behaviour during aromatherapy compared with placebo (median PAS scores 3 c.f. 4; Wilcoxon Signed‐Ranks test p = 0.016 (one‐tailed)).
Conclusions
Lavender oil administered in an aroma stream shows modest efficacy in the treatment of agitated behaviour in patients with severe dementia. Copyright © 2002 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## Setting Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events wit